Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid

Executive Summary

Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.

You may also be interested in...



Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement

The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement

The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Liraglutide Generics May Need More Robust Analytical Methods After Novo Petition

ANDA pathway is not sufficient to review liraglutide generics because of molecule's complexity, Novo contends; Teva appears to be first filer for Victoza.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel